Broker’s Call: Navin Flourine (Buy)

Why It Matters

The stock trades at a discount to historical valuation despite accelerating revenue and margin expansion, offering a potential upside for investors seeking exposure to the growing global fluorine‑based specialty chemicals market.

Key Takeaways

• Navin Fluorine's Q4 FY26 revenue rose 34% to ₹938 cr (~$114 M).
• CDMO segment grew 61%, driven by pharma and agro‑chemical contracts.
• HPP business benefits from R‑32 refrigerant demand and higher pricing.
• Forward P/E 43×, below five‑year average, indicating valuation upside.

Pulse Analysis

Navin Fluorine International has carved a niche in the global fluorine‑based chemicals space, operating across contract development and manufacturing (CDMO), specialty chemicals, and high‑performance products (HPP). Its backward‑integrated model and deep fluorine chemistry expertise enable it to serve pharma, agro‑chemical, refrigerant, and specialty‑material customers worldwide, with exports accounting for roughly 70% of sales. This diversified exposure positions the company to capture demand trends such as the shift toward low‑global‑warming‑potential refrigerants and specialty polymer applications.

Financially, the firm delivered a striking 34% revenue jump to ₹938 crore (about $114 million) in Q4 FY26, outpacing peers in the sector. Segmentally, CDMO revenues surged 61% on new pharma and agro‑chemical contracts, while Specialty Chemicals and HPP grew 39% and 20% respectively, underpinned by firm R‑32 pricing and higher plant utilization. EBITDA margins remain robust above 30%, and the stock now trades at a 43× forward P/E—well under its five‑year average—suggesting a valuation gap given the strong earnings trajectory.

Looking ahead to FY27, Navin Fluorine expects its recent capital investments to start generating revenue. The ramp‑up of R‑32 refrigerant production aligns with rising demand for environmentally friendly cooling solutions, and the debottlenecking of multi‑purpose plants should lift capacity utilization to around 80% in Specialty Chemicals. A strategic manufacturing and supply agreement with Chemours in the United States adds a high‑margin, long‑term revenue stream. Combined with a visible CDMO pipeline of 50‑55 molecules, these catalysts underpin the broker’s buy call and highlight the company’s potential to deliver sustained growth and shareholder value.